Gen­mab li­cens­es sec­ond mon­o­clon­al an­ti­body from Scan­cell

Gen­mab is li­cens­ing a sec­ond in­ves­ti­ga­tion­al an­ti-gly­can mon­o­clon­al an­ti­body from Scan­cell as part of an agree­ment inked be­tween the two com­pa­nies in 2022.

Scan­cell, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER